Applications of Ex Vivo Microscopy in Cancer Detection and Diagnosis

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: 31 August 2025 | Viewed by 1488

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical Engineering, Tulane University, New Orleans, LA 70118, USA
Interests: ex vivo microscopy; structured illumination; light sheet; tumor margins; biopsy; cancer

Special Issue Information

Dear Colleagues,

Ex vivo microscopy is a set of emerging microscopy methods intended for rapid, high-resolution imaging of excised tissue samples. These modalities have the ability to achieve depth-resolved images of fresh, fixed, and/or optically cleared tissues at microscopic resolution in clinically relevant timeframes. However, the choice of an optimal imaging modality and contrast mechanism is heavily influenced by the particular application to be addressed. This Special Issue aims to highlight the wide diversity in modalities and approaches in the field through their applications in cancer detection and diagnosis. Modalities may include, but are not limited to, optical sectioning microscopies (confocal, multiphoton, structured illumination, and light sheet), optical coherence tomography, photoacoustic microscopy, microscopy with UV excitation, vibrational microscopy., etc. Applications may include, but are not limited to, rapid on-site evaluation of cancer biopsy, surgical tumor margin assessment, primary cancer diagnosis, and rapid 2D or 3D imaging of intact samples.

Dr. J. Quincy Brown
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • microscopy
  • cancer
  • optical sectioning
  • diagnosis
  • detection

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 2164 KiB  
Article
Heterogeneous Formation of DNA Double-Strand Breaks and Cell-Free DNA in Leukemia T-Cell Line and Human Peripheral Blood Mononuclear Cells in Response to Topoisomerase II Inhibitors
by Christian Linke, Thilo von Hänisch, Julia Schröder, Werner Dammermann, Peter Markus Deckert, Mark Reinwald and Sandra Schwarzlose-Schwarck
Cancers 2024, 16(22), 3798; https://doi.org/10.3390/cancers16223798 - 12 Nov 2024
Viewed by 963
Abstract
Background: Improving precision medicine in chemotherapy requires highly sensitive and easily applicable diagnostic tools. In addition, non-invasive molecular real-time monitoring of cytotoxic response is highly desirable. Here, we employed the kinetics of DNA double-strand breaks (DSB) and cell-free DNA (cfDNA) in a cell [...] Read more.
Background: Improving precision medicine in chemotherapy requires highly sensitive and easily applicable diagnostic tools. In addition, non-invasive molecular real-time monitoring of cytotoxic response is highly desirable. Here, we employed the kinetics of DNA double-strand breaks (DSB) and cell-free DNA (cfDNA) in a cell model of topoisomerase II-inhibitors in T cell leukemia (Jurkat cells) compared to normal cells (peripheral blood mononuclear cells, PBMCs). Methods: We applied automated microscopy to quantify immuno-stained phosphorylated H2AX (γH2AX) as a marker for either DNA damage response (DDR) or cell death and quantitative PCR-based analysis of nuclear and mitochondrial cfDNA concentrations. Results: Jurkat cells displayed a DDR to cytotoxic drug treatment significantly earlier than PBMCs, and etoposide (ETP) induced DSB formation faster than doxorubicin (DOX) in both Jurkat and PBMCs. Jurkat cells exhibited an earlier cytotoxic response compared to PBMC, with a significantly increased mitochondrial cfDNA formation after 2 h of DOX application. In PBMCs, increased cell death was detected after 4 h of incubation with ETP, whereas DOX treatment was less effective. Conclusions: Both automated microscopy and mitochondrial cfDNA quantification analysis indicate that (malignant) Jurkat cells are more sensitive to DOX than (healthy) PBMC. Our real-time approach can improve DDR inducing drug selection and adaptation in cancer therapy and aids in decisions for optimal patient biosampling. Full article
(This article belongs to the Special Issue Applications of Ex Vivo Microscopy in Cancer Detection and Diagnosis)
Show Figures

Figure 1

Back to TopTop